Peer-reviewed article
ATRT-07. DEFINING LOST AND GAINED TRANSCRIPTIONAL REGULATORY NETWORKS IN ATYPICAL TERATOID RHABDOID TUMOR
Nesvick C, Zhang L, Wixom A, Hamdan F, Johnsen S et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This is a molecular biology research paper about atypical teratoid rhabdoid tumor (ATRT), a rare brain cancer in infants and young children. The study examines how loss of the SMARCB1 gene contributes to cancer development by analyzing changes in gene regulation and chromatin structure. While ATRT does affect children, this paper focuses on laboratory mechanisms in cell lines rather than evaluating interventions or measuring child well-being outcomes.
Key points
- ATRT is defined by bi-allelic loss of the SMARCB1 gene, which is the only recurrent genetic abnormality
- Restoring SMARCB1 in cancer cell lines reduced their ability to grow and reproduce
- SMARCB1 restoration caused widespread changes in chromatin accessibility and induced developmental gene expression patterns
- The study identified potential pioneer transcription factors whose function may be lost in ATRT
Limitations
This is basic molecular research using laboratory cell lines and does not evaluate any clinical intervention or treatment in children. It cannot inform us about treatment effectiveness, child outcomes, or real-world applicability.
Abstract
Abstract Atypical teratoid rhabdoid tumor (ATRT) is a central nervous system cancer of infancy and early childhood that may occur anywhere along the neuraxis and is associated with a high rate of mortality. While contemporary multimodal therapeutic approaches have significantly improved overall survival, targeted therapy remains elusive, and treatment is often associated with significant morbidity. ATRT is unique in its genomic stability, with the only recurrent genetic abnormality being bi-allelic loss of the SMARCB1 gene, which encodes a core subunit of the BAF chromatin remodeling complex. The epigenetic mechanisms by which SMARCB1 loss leads to tumorigenesis are not yet well-defined and addressing this gap in understanding is necessary for creating efficacious, targeted therapeutics. To better understand the epigenetic features gained and lost in ATRT, we re-expressed SMARCB1 in a library of patient-derived and established ATRT cell lines of multiple molecular subtypes. SMARCB1 restoration significantly reduced or eliminated the proliferative and clonogenic capacity of each cell line. We performed assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-Seq) and RNA sequencing (RNA-Seq) to define putative transcriptional regulatory networks that are gained and lost in ATRT. SMARCB1 restoration was associated with global changes in chromatin openness consistent with the creation of new regulatory elements throughout the genome, and these were associated with induction of a diverse developmental transcriptional signature. Motif enrichment analysis of regions with increased accessibility defined a small but consistent number of centrally enriched transcription factor motifs across cell lines indicative of putative pioneer factors whose functions may be lost in ATRT. Pertinent chromatin immunoprecipitation with sequencing (ChIP-Seq) data will be discussed in the context of lost and gained transcriptional regulatory networks in ATRT and normal cellular development.